Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review

Orit Kaidar-Person, Salem Billan, Abraham Kuten

Research output: Contribution to journalReview articlepeer-review

Abstract

Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.

Original languageEnglish
Pages (from-to)704-706
Number of pages3
JournalMedical Oncology
Volume29
Issue number2
DOIs
StatePublished - Jun 2012
Externally publishedYes

Keywords

  • Carcinoma
  • Ductal carcinoma
  • HER-2
  • Human epidermal growth factor receptor-2
  • Salivary gland
  • Targeted therapy
  • Trastuzumab

Fingerprint

Dive into the research topics of 'Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review'. Together they form a unique fingerprint.

Cite this